Alan Ashworth

发表

Materials and Methods with respect to the identification and sequencing of the BRCA2 cancer-suszeptilitaetsgens and its applications

Phillip Andrew Futreal, Richard Wooster, Alan Ashworth, 1996 .

IDENTIFICATION OF NOVEL FUSION GENES IN PAEDIATRIC HIGH GRADE GLIOMA

Chris Jones, Darren Hargrave, Alan Ashworth, 2012 .

H3F3A MUTATIONS IN PAEDIATRIC GLIOBLASTOMA REGULATE A SELF-RENEWAL GENE SIGNATURE

Paul Workman, Rui L. Reis, Darren Hargrave, 2012 .

INTEGRATED WHOLE GENOME AND RNA SEQUENCING IDENTIFIES NOVEL EXPRESSED FUSION TRANSCRIPTS IN PAEDIATRIC HIGH GRADE GLIOMA

Rui L. Reis, Alan Mackay, Darren Hargrave, 2013 .

Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast

Julian Peto, Matthias W. Beckmann, Peter A. Fasching, 2014, PLoS genetics.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Paul Ellis, Nazneen Rahman, Alexander Gutin, 2018, Nature Medicine.

DAISY: picking synthetic lethals from cancer genomes.

Alan Ashworth, Colm J Ryan, A. Ashworth, 2014, Cancer cell.

Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation

Alan Mackay, Chris Jones, Alan Ashworth, 2007, Laboratory Investigation.

Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity.

Alan Ashworth, Bhargav A. Patel, A. Ashworth, 2019, Journal of medicinal chemistry.

Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR

Alan Ashworth, A. Ashworth, H. Gevensleben, 2013, Clinical Cancer Research.

Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type

Magali Lacroix-Triki, Alan Ashworth, Felipe C Geyer, 2010, The Journal of pathology.

Xist has properties of the X-chromosome inactivation centre

Alan Ashworth, A. Ashworth, Laura B. K. Herzing, 1997, Nature.

Structural basis for recruitment of BRCA2 by PALB2

Alan Ashworth, Laurence H Pearl, A. Ashworth, 2009, EMBO reports.

Evolutionary rate of a gene affected by chromosomal position

Alan Ashworth, A. Ashworth, Jo Perry, 1999, Current Biology.

Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance

Alan Ashworth, Mitch Dowsett, A. Ashworth, 2006, Breast Cancer Research and Treatment.

Identification of the breast cancer susceptibility gene BRCA2

Julian Peto, Peter Devilee, Rosalind Eeles, 1996, Nature.

Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction

Kei Sakamoto, Alan Ashworth, A. Ashworth, 2005, The EMBO journal.

Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data

C. V. Jongeneel, Christian Iseli, Brian J. Stevenson, 2006, Breast Cancer Research.

High-throughput RNAi screening reveals novel regulators of telomerase.

Cristina Naceur-Lombardelli, Alan Ashworth, A. Ashworth, 2011, Cancer research.

19p13.1 is a triple-negative-specific breast cancer susceptibility locus.

Daniel J. Park, Julian Peto, Kamila Czene, 2012, Cancer research.

Gene expression following ionising radiation: Identification of biomarkers for dose estimation and prediction of individual response

Christophe Badie, Alan Mackay, Alan Ashworth, 2011, International journal of radiation biology.

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

Hugo M. Horlings, Alan Mackay, Alan Ashworth, 2009, Oncogene.

Genomics: Comparisons across cancers

Thomas J. Hudson, Alan Ashworth, T. Hudson, 2013, Nature.

BRCAness revisited

Alan Ashworth, Christopher J. Lord, A. Ashworth, 2016, Nature Reviews Cancer.

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis

Gary D. Bader, Christine L. Clarke, Gary D Bader, 2020, Nature Communications.

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

Wei Lu, Wei Zheng, Mads Thomassen, 2013, Nature Genetics.

FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas

Alan Mackay, Chris Jones, Alan Ashworth, 2006, Clinical Cancer Research.

PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas

Marketa Zvelebil, Alan Mackay, Alan Ashworth, 2009, Clinical Cancer Research.

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

Elizabeth Iorns, Alan Ashworth, A. Ashworth, 2008, The EMBO journal.

Searching for synthetic lethality in cancer.

Alan Ashworth, A. Ashworth, C. Lord, 2011, Current opinion in genetics & development.

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

Alan Ashworth, A. Ashworth, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Genetic Variants at 8q24 with Breast Cancer Risk

Julian Peto, Isabel dos Santos Silva, Olivia Fletcher, 2008, Cancer Epidemiology Biomarkers & Prevention.

The relationship between the roles of BRCA genes in DNA repair and cancer predisposition.

Alan Ashworth, A. Ashworth, A. Tutt, 2002, Trends in molecular medicine.

PARP inhibitors: Synthetic lethality in the clinic

Alan Ashworth, Christopher J. Lord, A. Ashworth, 2017, Science.

Retroviral vectors for establishing tetracycline-regulated gene expression in an otherwise recalcitrant cell line

Alan Ashworth, Tariq Enver, A. Ashworth, 2002, BMC Molecular Biology.

BRCA1 and BRCA2 as ovarian cancer susceptibility genes.

Alan Ashworth, A. Ashworth, H. Sowter, 2005, Carcinogenesis.

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

Jung-Sik Kim, Alan Ashworth, A. Ashworth, 2009, EMBO molecular medicine.

Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)

Patrick Neven, Hui Zhao, Nazneen Rahman, 2012, PloS one.

Stem cells and breast cancer: A field in transit

Alan Ashworth, A. Ashworth, M. Smalley, 2003, Nature Reviews Cancer.

Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement

Jorge S. Reis-Filho, Alan Mackay, Alan Ashworth, 2011, Journal of the National Cancer Institute.

The product of the mouse Xist gene is a 15 kb inactive X-specific transcript containing no conserved ORF and located in the nucleus

Dominic P. Norris, Alan Ashworth, Neil Brockdorff, 1992, Cell.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Wei Yuan, Nina Tunariu, Rosalind Eeles, 2015, The New England journal of medicine.

High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing

Marketa Zvelebil, Alan Ashworth, Costas Mitsopoulos, 2011, Genome Biology.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Quynh-Thu Le, Martin G Pomper, Levi Garraway, 2017, The Lancet. Oncology.

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

Jan Lubinski, Alan Ashworth, Susan Shanley, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mechanisms of Disease: angiogenesis and the management of breast cancer

Alan Ashworth, Mitch Dowsett, A. Ashworth, 2007, Nature Clinical Practice Oncology.

Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium.

Michael Jones, Nazneen Rahman, Michael Bremer, 2011, Human molecular genetics.

A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium.

Julian Peto, Kyriaki Michailidou, Thomas Brüning, 2014, Human molecular genetics.

Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines

Alan Mackay, Chris Jones, Alan Ashworth, 2008, Laboratory Investigation.

Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

Patrick Neven, Peter Kraft, Nazneen Rahman, 2015 .

Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets

Elizabeth Iorns, Jorge S. Reis-Filho, Alan Ashworth, 2009, PloS one.

An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor.

Marketa Zvelebil, Stuart M Haslam, Anne Dell, 2014, Cancer discovery.

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

Eliana Marinari, Alan Ashworth, James Campbell, 2016, PloS one.

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines

Bissan Al-Lazikani, Sandra J. Strauss, Wenbin Wei, 2016, Cell reports.

Bringing DNA Repair in Tumors into Focus

Alan Ashworth, Christopher J Lord, 2009, Clinical Cancer Research.

Investigation of gene‐environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors

Thomas Brüning, Kamila Czene, Ute Hamann, 2015, International journal of cancer.

Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways.

Christopher G Mathew, Alan Ashworth, S. West, 2004, Human molecular genetics.

Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers.

Wei Lu, Päivi Heikkilä, Peter Kraft, 2013, American journal of human genetics.

Genome-wide association studies identify four ER negative–specific breast cancer risk loci

Patrick Neven, Michael Jones, Wei Lu, 2013, Nature Genetics.

Receptor and secreted targets of Wnt-1/β-catenin signalling in mouse mammary epithelial cells

Alan Ashworth, Tariq Enver, A. Ashworth, 2005, BMC Cancer.

Functional viability profiles of breast cancer.

Alan Mackay, Alan Ashworth, Daniel Wetterskog, 2011, Cancer discovery.

3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase

Colin B. Reese, Alan Ashworth, Dario R. Alessi, 1997, Current Biology.

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

Alan Ashworth, James Campbell, Kerry Fenwick, 2014, Cancer research.

Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study

Patrick Neven, Chiun-Sheng Huang, Julian Peto, 2014, Breast Cancer Research.

Resistance to therapy caused by intragenic deletion in BRCA2

Jorge S. Reis-Filho, Alan Ashworth, Christopher J. Lord, 2008, Nature.

Analysis of PALB2/FANCN-associated breast cancer families

Petra M. Nederlof, Jorge S. Reis-Filho, David M. Livingston, 2007, Proceedings of the National Academy of Sciences.

PALB2,CHEK2 and ATM rare variants and cancer risk: Data from COGS

Dong Liang, Jane E. Carpenter, Peter Kraft, 2016 .

Drug resistance caused by reversion mutation.

Alan Ashworth, A. Ashworth, 2008, Cancer research.

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

Trey Ideker, Claudia Hernandez-Armenta, Brian K. Shoichet, 2020, bioRxiv.

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.

Alan Ashworth, A. Ashworth, A. Tutt, 2015, Annual review of medicine.

Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene‐Environment Interactions

Patrick Neven, Michael Jones, Julian Peto, 2014, Genetic epidemiology.

Synthetic lethal approaches to breast cancer therapy

Alan Ashworth, Christopher J. Lord, A. Ashworth, 2010, Nature Reviews Clinical Oncology.

Translating cancer research into targeted therapeutics

Alan Ashworth, A. Ashworth, J. Bono, 2010, Nature.

Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue

Alan Ashworth, Jorge S Reis-Filho, Robin L. Jones, 2006, Modern Pathology.

11q13 is a susceptibility locus for hormone receptor positive breast cancer

Patrick Neven, Michael Jones, Michael Bremer, 2012, Human mutation.

Mechanisms of resistance to therapies targeting BRCA-mutant cancers

Alan Ashworth, A. Ashworth, C. Lord, 2013, Nature Medicine.

Neuregulin3 alters cell fate in the epidermis and mammary gland

Alan Ashworth, A. Ashworth, S. Parry, 2007, BMC Developmental Biology.

Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study.

Michael Jones, Julian Peto, Simon Heath, 2011, Journal of the National Cancer Institute.

BRCA2 mutations in primary breast and ovarian cancers

Sheila Seal, Richard Wooster, Alan Ashworth, 1996, Nature Genetics.

Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.

Wei Lu, Nina Ditsch, Julian Peto, 2013, American journal of human genetics.

Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk.

Michael Jones, Paolo Vineis, Salvatore Panico, 2012, Cancer research.

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

Alan Ashworth, Nuala McCabe, A. Ashworth, 2006, Cancer research.

Reprogramming human T cell function and specificity with non-viral genome targeting

Jonathan S. Weissman, Alan Ashworth, Antoni Ribas, 2017, Nature.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Alan Ashworth, Ian Hickson, Nuala McCabe, 2005, Nature.

Genome-wide association analysis identifies three new breast cancer susceptibility loci

Michael Jones, Nazneen Rahman, Daniel J. Park, 2012, Nature Genetics.

Germline mutations in RAD51D confer susceptibility to ovarian cancer

Deborah Hughes, Nazneen Rahman, Elise Ruark, 2011, Nature Genetics.

Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization.

Elizabeth Iorns, Alan Ashworth, A. Ashworth, 2009, The Biochemical journal.

Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer

Peter Donnelly, Mark I. McCarthy, Nazneen Rahman, 2012, Nature.

The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis

Alan Mackay, Alan Ashworth, Mitch Dowsett, 2006, Breast Cancer Research.